Remote Ischaemic Preconditioning in Childhood Cancer

Not Applicable

Completed

• Conditions: Cardiotoxicity
• Interventions: Procedure: Remote Ischaemic Preconditioning; Other: Control

• Registration Number: NCT03166813
• Lead Sponsor: The University of Hong Kong

Brief Summary

Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern. Exploration of new strategies to protect the heart in the long term is therefore of paramount importance in children undergoing treatment of cancers. Previous cardioprotective interventions hav focused on changing the formulation or rate of administration of anthracyclines but with no observable benefits. While dexrazoxane, an iron chelator, has shown to reduce cardiotoxic outcomes, there remains worries of an association between dexrazoxane use and an increased risk of developing secondary malignancies. Recently, the clinical application of remote ischaemic preconditioning (RIPC) as a non-invasive and an easily applicable non-pharmacological myocardial protective intervention has gained increasing interest. Remote ischaemic preconditioning is the phenomenon in which brief episodes of reversible ischaemia and reperfusion applied to one vascular bed render resistance to ischaemia reperfusion injury of tissues and organs distant away. It can be achieved by repeated 5-minute cycles of inflation and deflation of blood pressure cuff placed over the arm or leg to induce limb ischaemia and reperfusion injury. It is noteworthy that anthracycline cardiotoxicity and myocardial reperfusion injury occur through similar pathways. Hence, the investigators hypothesize that RIPC may reduce myocardial injury in children receiving anthracycline chemotherapy for childhood malignancies. The proposed study aims to conduct a parallel-group blinded randomized controlled trial study to investigate whether RIPC may reduce heart damage in childhood cancer patients undergoing anthracycline-based treatment, and to determine the effect of RIPC on the changes in levels of cardiac troponin T, and on the occurrence of clinical cardiovascular events and echocardiographic indices.

Detailed Description

Remote ischemic preconditioning (RIPC) protocol will be induced at baseline and before each dose of anthracycline cardiac surgery and once before induction of anesthesia by 3 cycles of 5-min upper or lower limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-05-16
• Study First Submitted QC: 2017-05-24
• Study First Posted: 2017-05-25
• Study Start: 2017-07-01
• Status Verified: 2022-06
• Primary Completion: 2022-06-01
• Study Completion: 2022-06-01
• Last Update Submitted: 2022-06-07
• Last Update Posted: 2022-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

• patients aged 4 to 18 years old
• newly diagnosed patients with solid tumours or haematological malignancies referred for anthracycline-based chemotherapy
• no history of being treated with anthracycline-based regimens in the past.

Read More

Exclusion Criteria

• existence of congenital or acquired heart disease
• presence of syndromal disorders
• abnormal baseline echocardiographic assessment
• peripheral vascular disease that renders RIPC impossible
• a platelet count <30,000/µL.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention RIPC	Remote Ischaemic Preconditioning	The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
Control	Control	The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.

Primary Outcome Measures

Name	Time	Method
High sensitivity cardiac troponin T (hs-cTnT)	hs-cTnT will be measured at baseline, and at 3 months after completion of all anthracycline. The change from baseline hs-cTnT to at 3 months after completion of all anthracycline will be measured.	Biomarker of myocardial injury

Secondary Outcome Measures

Name	Time	Method
Occurrence of clinical cardiovascular events	at baseline, within 1 week and at 3 months after completion of all anthracycline treatment.	Clinical cardiovascular events include development of clinical congestive heart failure, occurrence of cardiac arrhythmias, the need to institute cardiac medications, and cardiac death
Echocardiographic assessment of left ventricular function	Echocardiographic assessment will be performed at baseline, and within 1 week and at 3 months after completion of all anthracycline treatment.	left ventricular systolic and diastolic function

Trial Locations

Locations (1)

Hong Kong Children's Hospital; 🇭🇰 Hong Kong, Hong Kong